Compare FPH & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPH | FHTX |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 364.6M | 323.4M |
| IPO Year | 2013 | 2020 |
| Metric | FPH | FHTX |
|---|---|---|
| Price | $5.00 | $3.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 168.4K | 146.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $110,020,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | N/A | $20.13 |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $4.60 | $3.27 |
| 52 Week High | $6.64 | $6.95 |
| Indicator | FPH | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 35.31 |
| Support Level | $4.89 | $3.62 |
| Resistance Level | $5.16 | $5.84 |
| Average True Range (ATR) | 0.16 | 0.27 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 69.91 | 13.33 |
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.